Cullgen, founded in 2018, is a biopharmaceutical company that develops new chemical entities (NCEs) designed to treat diseases that lack effective therapeutic approaches. Using its proprietary uSMITE™ platform, the company expands on the drug design paradigm aiming to target proteins that are typically resistant to treatments for selective destruction. Cullgen has produced several highly potent, selective, and bioavailable targeted protein degrader compounds. Cullgen is headquartered in San Diego, California.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/08/2023 | Series C | $35MM | $xx.xx | $264.09MM | ||
Price per Share
$xx.xx
Shares Outstanding
13,329,269
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
|
||||||
02/25/2021 | Series B | $50MM | $xx.xx | $184.64MM | ||
Price per Share
$xx.xx
Shares Outstanding
20,080,321
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
|
||||||
04/10/2019 | Series A | $16MM | $xx.xx | $75.45MM | ||
Price per Share
$xx.xx
Shares Outstanding
9,411,765
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
|
||||||
03/10/2018 | Series Seed-2 | $5MM | $xx.xx | $30MM | ||
Price per Share
$xx.xx
Shares Outstanding
5,000,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
|
||||||
03/10/2018 | Series Seed-1 | $10MM | $xx.xx | $30MM | ||
Price per Share
$xx.xx
Shares Outstanding
10,000,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
|